

# Multinational Clinical Trial Review and Administration in China

Chief of Review management , Feng Yi Centre for Drug Evaluation State Food & Drug Administration

### **Legislation in China**

#### • Drug Administration Law of P. R. China

- Manufacturers
- Distributors
- Pharmaceuticals in Medical Institutions
- Drug Administration
- etc

- Regulations for Implementation of the Drug Administration Law of P. R. China
  - Detail Requirements of the Law
  - Definition of New Drug, Period of monitoring for New Drug, Data Protection
  - etc
- Provisions for Drug Registration
  - Definition of the Drug registration
  - Category of Drug Registration Procedure
- Relevant Practise and Guidance
  - GCP/GLP/GMP Guidance

### Practices & Guidance

WALUA

Jav

Regulation

Provision

# **Requirement of the Provision on Multinationals Clinical Trial**

### Before 2002


No detail requirement Some R&D trial conduct in hospital

### After 2002

The provision for drug registration set relevant item, make the clear requirement to conduct multinational trial in China

### **Drug registration Procedure**

0



# **Responsible Organization**

<u></u>


<b>Centre for Reception</b>	Receipt dossier Screen the file
Department of Drug Registration, SFDA	Issue relevant provision Issue guidance Make clinical and marketing Decision, etc,
<b>Centre for drug evaluation</b>	Take charge the technical review
National Institute of China Pharmaceutical and Biological Product	Validate and test the sample ,etc
Department of drug Safety Supervision, SFDA	Supervise the clinical trial, etc

UAYTO

### **Staff in Centre for Drug Evaluation (1)**




### **Staff in Centre for Drug Evaluation (2)**



### **Structure of Centre for Drug Evaluation**

6.




# **Review Stream Line**

#### Chemical Drug

- Oncology, Respiration, Anti-infection, Cardio-Renal, Gastrointestinal product, etc(13, fields)
- TCM
  - Oncology, Respiration, Cardio-Renal, Gastrointestinal product, etc(14, fields)
- Biological product
  - Vaccine, Biological product for treatment, Diagnostic reagents in vitro

# **IND Review Procedure**


0




### **IND** review focus on

- Safety
  - Protocol and Plan
  - Pharmacological and toxicological data
  - CM&C
- Conclusion of the technical review
  - Submission detail data by sponsor
  - Disapproval (Clinical Hold)
  - Approval


Consult outside experts when there are some important question



# **Type of IND**




### **Multinational trial in China from 2002 to 2008**




### **Phase of trial**

0




### **Review time of multinational trial (1)**



### **Review time multinational trial (2)**

**C**-




### **Review time multinational trial (3)**

### • The main reason of > 4M review

Protocol	Not very clear, need sponsor answer question
Quality of data	Not satisfy the requirement
Communication	Local sponsor need get the support from the oversea headquarters
Shortage of evaluators	Cde need recruit more staff

### **The result of review**

**C** 





### **Need to be solved in future**

Regulatory science	IND function need sound establishPossibility of conduct the phasetrial
Operation and performance	CDE review and IRB review More evaluators
Clinical R&D process	Safety report system
Guidance	ICH E5
Cooperation and communication	Other agency ,PMDA、KFDA, etc. Sponsor
	E E E E E E E E E E E E E E E E E E E

cde sda

CEN



Beijing 2008





2000 EVALUAT

Pan lo

OBMTER 1

1.00

EVALUAT EVALUAT